By maximizing clinical and economic benefits through precision-guided patient selection, dupilumab’s dual IL-4/IL-13 blockade makes it a versatile biologic—especially suited for T2-high and overlapping asthma phenotypes or patients with comorbidities such as nasal polyps, eosinophilic esophagitis, and atopic dermatitis. This evidence concerns the gene IL4 and atopic eczema.